0001209191-19-007326.txt : 20190205 0001209191-19-007326.hdr.sgml : 20190205 20190205161651 ACCESSION NUMBER: 0001209191-19-007326 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190201 FILED AS OF DATE: 20190205 DATE AS OF CHANGE: 20190205 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ambrogi Michael J. CENTRAL INDEX KEY: 0001654363 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37565 FILM NUMBER: 19568112 MAIL ADDRESS: STREET 1: 195 COMMERCE WAY CITY: PORTSMOUTH STATE: NH ZIP: 03801 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NovoCure Ltd CENTRAL INDEX KEY: 0001645113 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF BUSINESS PHONE: 44 (0)15 3475 6700 MAIL ADDRESS: STREET 1: NO. 4 THE FORUM STREET 2: GRENVILLE STREET CITY: ST. HELIER STATE: Y9 ZIP: JE2 4UF FORMER COMPANY: FORMER CONFORMED NAME: Novocure Ltd DATE OF NAME CHANGE: 20150615 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-02-01 0 0001645113 NovoCure Ltd NVCR 0001654363 Ambrogi Michael J. C/O NOVOCURE INC. 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN PA 19355 0 1 0 0 Chief Operating Officer Ordinary Shares 2019-02-01 4 M 0 37500 7.15 A 184058 D Ordinary Shares 2019-02-01 4 S 0 27660 48.861 D 156398 D Ordinary Shares 2019-02-01 4 S 0 9840 49.508 D 146558 D Ordinary Shares 2019-02-04 4 M 0 21000 7.15 A 167558 D Ordinary Shares 2019-02-04 4 S 0 21000 49.533 D 146558 D Options to Buy Ordinary Shares 7.15 2019-02-01 4 M 0 37500 0.00 D 2027-02-21 Ordinary Shares 37500 182513 D Options to Buy Ordinary Shares 7.15 2019-02-04 4 M 0 21000 0.00 D 2027-02-21 Ordinary Shares 21000 161513 D Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi. On February 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 27,660 shares in multiple trades at prices ranging from $48.33 to $49.32. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. On February 1, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 9,840 shares in multiple trades at prices ranging from $49.33 to $49.94. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. On February 4, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Ambrogi, Mr. Ambrogi sold 21,000 shares in multiple trades at prices ranging from $49.08 to $49.75. The price reported above reflects the weighted average sale price. Mr. Ambrogi hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Fully vested as of the date hereof. /s/ Kimberly Burke, Attorney in fact for Michael J. Ambrogi 2019-02-05